Y Furuya

Summary

Affiliation: Toyama Medical and Pharmaceutical University
Country: Japan

Publications

  1. ncbi request reprint Prostate-specific antigen, prostate volume and transition zone volume in Japanese patients with histologically proven benign prostatic hyperplasia
    Y Furuya
    Department of Urology, Teikyo University School of Medicine, Ichihara Hopsital, Ichihara, Japan
    Int Urol Nephrol 33:645-8. 2001
  2. ncbi request reprint Serum soluble Fas level for detection and staging of prostate cancer
    Y Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani, Japan
    Anticancer Res 21:3595-8. 2001
  3. ncbi request reprint Effect of Bu-zhong-yi-qi-tang on seminal plasma cytokine levels in patients with idiopathic male infertility
    Y Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930 0194, Japan
    Arch Androl 50:11-4. 2004
  4. ncbi request reprint Cell proliferation, apoptosis and prognosis in patients with metastatic prostate cancer
    Yuzo Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930 0194, Japan
    Anticancer Res 23:577-81. 2003
  5. ncbi request reprint Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer
    Yuzo Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930 0194, Japan
    Urol Int 70:195-9. 2003
  6. ncbi request reprint Preoperative parameters to predict tumor volume in Japanese patients with nonpalpable prostate cancer
    Yuzo Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930 0194, Japan
    Int J Clin Oncol 7:109-13. 2002
  7. ncbi request reprint Comparison of T1c versus T2 prostate cancers in Japanese patients undergoing radical prostatectomy
    Y Furuya
    Department of Urology, Teikyo University School of Medicine, Ichihara Hospital, Japan
    Int Urol Nephrol 33:73-6. 2002
  8. ncbi request reprint External beam radiation monotherapy for prostate cancer
    K Akakura
    Department of Urology, Chiba University School of Medicine, Japan
    Int J Urol 6:408-13. 1999
  9. ncbi request reprint Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels
    Y Furuya
    Department of Urology, Teikyo University School of Medicine, Ichihara Hospital, Anesaki 3426 3, Ichihara, Chiba 299 0111, Japan
    Anticancer Res 21:1317-20. 2001
  10. ncbi request reprint Changes in serum prostate-specific antigen following prostatectomy in patients with benign prostate hyperplasia
    Y Furuya
    Department of Urology, Chiba University School of Medicine, Japan
    Int J Urol 7:447-51. 2000

Collaborators

Detail Information

Publications38

  1. ncbi request reprint Prostate-specific antigen, prostate volume and transition zone volume in Japanese patients with histologically proven benign prostatic hyperplasia
    Y Furuya
    Department of Urology, Teikyo University School of Medicine, Ichihara Hopsital, Ichihara, Japan
    Int Urol Nephrol 33:645-8. 2001
    ..315 to 0.439. In patients with LUTS and clinical BPH, serum PSA increased with age and was related to prostate volume. PSA might be useful for therapeutic decision making for patients with symptomatic BPH...
  2. ncbi request reprint Serum soluble Fas level for detection and staging of prostate cancer
    Y Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani, Japan
    Anticancer Res 21:3595-8. 2001
    ..sFas levels might be useful as a discriminator between prostate cancer and BPH while sFas might indicate the tumor burden in patients with prostate cancer...
  3. ncbi request reprint Effect of Bu-zhong-yi-qi-tang on seminal plasma cytokine levels in patients with idiopathic male infertility
    Y Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930 0194, Japan
    Arch Androl 50:11-4. 2004
    ..Seminal plasma IL-8 level did not change. Certain kinds of cytokine in the seminal plasma might play some role in improving semen quality with treatment...
  4. ncbi request reprint Cell proliferation, apoptosis and prognosis in patients with metastatic prostate cancer
    Yuzo Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930 0194, Japan
    Anticancer Res 23:577-81. 2003
    ....
  5. ncbi request reprint Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer
    Yuzo Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930 0194, Japan
    Urol Int 70:195-9. 2003
    ..To evaluate prognostic factors in metastatic prostate cancer, patients who had been treated with endocrine therapy were investigated especially for the change in prostate volume...
  6. ncbi request reprint Preoperative parameters to predict tumor volume in Japanese patients with nonpalpable prostate cancer
    Yuzo Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930 0194, Japan
    Int J Clin Oncol 7:109-13. 2002
    ..To predict potentially insignificant cancer, which is a candidate for delayed treatment, patients whose biopsy specimen showed relatively favorable features were also examined...
  7. ncbi request reprint Comparison of T1c versus T2 prostate cancers in Japanese patients undergoing radical prostatectomy
    Y Furuya
    Department of Urology, Teikyo University School of Medicine, Ichihara Hospital, Japan
    Int Urol Nephrol 33:73-6. 2002
    ..T1c cancers were clinically significant and clinicopathological features of Tlc tumors were similar to T2a tumors. PSA measurement could detect potentially curable prostate cancer...
  8. ncbi request reprint External beam radiation monotherapy for prostate cancer
    K Akakura
    Department of Urology, Chiba University School of Medicine, Japan
    Int J Urol 6:408-13. 1999
    ..To clarify the implications and limitations of external beam radiation monotherapy for localized prostate cancer, the long-term outcomes and prognostic factors were investigated...
  9. ncbi request reprint Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels
    Y Furuya
    Department of Urology, Teikyo University School of Medicine, Ichihara Hospital, Anesaki 3426 3, Ichihara, Chiba 299 0111, Japan
    Anticancer Res 21:1317-20. 2001
    ..The present study demonstrated that PSATZ was superior to PSA as a predictor of extracapsular invasion in intermediate PSA levels. Measurement of PSATZ may be of additional value to indicate the need for radical prostatectomy...
  10. ncbi request reprint Changes in serum prostate-specific antigen following prostatectomy in patients with benign prostate hyperplasia
    Y Furuya
    Department of Urology, Chiba University School of Medicine, Japan
    Int J Urol 7:447-51. 2000
    ..To investigate how prostatectomy for patients with benign prostate hyperplasia (BPH) affected the serum prostate-specific antigen (PSA) levels...
  11. ncbi request reprint Radiotherapy for local progression in patients with hormone-refractory prostate cancer
    Y Furuya
    Department of Urology, School of Medicine, Chiba University, Japan
    Int J Urol 6:187-91. 1999
    ..The aim of the present study was to investigate the effect of radiotherapy on the local progression of hormone-refractory prostate cancer...
  12. ncbi request reprint Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate
    K Akakura
    Department of Urology, School of Medicine, Chiba University, Japan
    Eur Urol 33:567-71. 1998
    ..This paper would like to contribute to this effort by describing the endocrine withdrawal phenomenon in patients treated with combinations of castration plus chlormadinone acetate, ethynylestradiol or estramustine phosphate...
  13. ncbi request reprint Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment
    Y Furuya
    Department of Urology, School of Medicine, Chiba University, Japan
    Int Urol Nephrol 32:659-63. 2001
    ..In metastatic prostate cancer patients treated with androgen withdrawal, serial measurement of PSA could distinguish nonfavorable responders early in the course of treatment and assist in monitoring for disease progression...
  14. ncbi request reprint Prognosis of patients with T4 prostate carcinoma
    Y Furuya
    Department of Urology, School of Medicine, Chiba University, Japan
    Int J Urol 6:192-5. 1999
    ..The clinical course of patients with T4 prostate carcinoma was examined in order to consider whether there are alternative treatment options besides androgen ablation therapy...
  15. ncbi request reprint Endocrine therapy for recurrence after definitive radiotherapy in patients with prostate cancer
    Y Furuya
    Department of Urology, Chiba University School of Medicine, Chiba, Japan
    Int J Urol 8:222-6. 2001
    ..Long-term results were analyzed to evaluate the role of endocrine therapy in the management of local and distant recurrence of prostate cancer following external radiation therapy...
  16. ncbi request reprint Pattern of progression and survival in hormonally treated metastatic prostate cancer
    Y Furuya
    Department of Urology, School of Medicine, Chiba University, Japan
    Int J Urol 6:240-4. 1999
    ..To further evaluate disease progression, the pattern of progression and survival in hormonally treated metastatic prostate cancer was examined...
  17. ncbi request reprint Effect of prostatic biopsy on free-to-total prostate-specific antigen ratio in patients with prostate cancer
    Y Furuya
    Department of Urology, Teikyo University School of Medicine, Ichihara Hospital, Chiba, Japan
    Int J Urol 7:49-53. 2000
    ....
  18. ncbi request reprint Soluble Fas and interleukin-6 and interleukin-8 levels in seminal plasma of infertile men
    Y Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930 0194, Japan
    Arch Androl 49:449-52. 2003
    ..Seminal plasma IL-8 was not correlated with sperm parameters. It would appear that certain kinds of cytokine in the seminal plasma might play an important role in improving semen quality...
  19. ncbi request reprint Serum immunosuppressive acidic protein as a potent prognostic factor for patients with metastatic renal cell carcinoma
    T Igarashi
    Department of Urology, Chiba University School of Medicine, Japan
    Jpn J Clin Oncol 31:13-7. 2001
    ..We analyzed serum immunosuppressive acidic protein (IAP) levels and the cutoff value, then tested its validity for assessing patients' prognoses...
  20. ncbi request reprint Mapping of metastasis suppressor genes for prostate cancer by microcell-mediated chromosome transfer
    T Ichikawa
    Department of Urology, Chiba University School of Medicine, Japan
    Asian J Androl 2:167-71. 2000
    ..To identify the metastasis suppressor genes for prostate cancer...
  21. ncbi request reprint Metastatic prostate cancer with normal level of serum prostate-specific antigen
    R Nishio
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan
    Int Urol Nephrol 35:189-92. 2003
    ..In advanced prostate cancer patients with low PSA level, those markers may aid in the follow up of disease...
  22. ncbi request reprint Clinical significance of pulmonary metastases in stage D2 prostate cancer patients
    H Nakamachi
    Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan
    Prostate Cancer Prostatic Dis 5:159-63. 2002
    ..These data suggest that the presence of pulmonary metastasis has no ominous impact on clinical course and disease outcome even in patients with disseminated prostate cancer...
  23. ncbi request reprint Persistent Müllerian duct syndrome: a surgical approach
    R Nishio
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930 0194, Japan
    Arch Androl 49:479-82. 2003
    ..Physical examination showed a normal and an empty scrotum with a nonpalpable gonad. Chromosome analysis revealed 46,XY. Pathological findings demonstrated the immature testis and the immature uterus...
  24. ncbi request reprint Tissue factor expression and prognosis in patients with metastatic prostate cancer
    Takuya Akashi
    Department of Urology, Toyama Medical and Pharmaceutical University Faculty of Medicine, Sugitani, Toyama, Japan
    Urology 62:1078-82. 2003
    ..To assess immunohistochemically the pattern of tissue factor (TF) expression in patients with metastatic prostate cancer, because TF is aberrantly expressed in human cancer. TF is the primary initiator of the coagulation cascade...
  25. ncbi request reprint Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy
    Kazuhiro Araki
    Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan
    Urology 68:1178-82. 2006
    ..To identify the prognostic factors in patients with recurrent renal cell carcinoma after nephrectomy, various factors were assessed, with special attention to serum immunosuppressive acidic protein (IAP) and its doubling time...
  26. ncbi request reprint Differential expression of integrin subunits in DU-145/AR prostate cancer cells
    Osamu Nagakawa
    Department of Pathogenic Biochemistry, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Toyama 930 0194, Japan
    Oncol Rep 12:837-41. 2004
    ..These results indicate that androgen receptor may play a role in the regulation of adhesion to the extracellular matrices and invasion of prostate cancer cells through influencing the expression of specific integrin subunits...
  27. ncbi request reprint The effect of eicosapentaenoic acid on prostate-specific antigen
    Kei Hamazaki
    Division of Clinical Application, Department of Clinical Sciences, Institute of Natural Medicine, University of Toyama, Toyama, Japan
    In Vivo 20:397-401. 2006
    ..5+/-14.0%). There were no significant differences between the two groups in the serum PSA levels, allowing the conclusion that the PSA is an appropriate surrogate marker of recurrence in prostate cancer...
  28. ncbi request reprint [Treatment of traditional Chinese medicine for idiopathic male infertility]
    Yuzo Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University
    Hinyokika Kiyo 50:545-8. 2004
    ..To make the best use of traditional medicine, it is important to give medication according to the traditional diagnosis (Sho)...
  29. ncbi request reprint Prognostic significance of serum soluble Fas level and its change during regression and progression of advanced prostate cancer
    Yuzo Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan
    Endocr J 50:629-33. 2003
    ..sFas ligand levels were very low or below measurable levels in all specimens. sFas levels might be associated with poor prognosis in metastatic prostate cancer. Serum sFas ligand appears to have limited clinical relevance...
  30. ncbi request reprint Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer
    Yuzo Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan
    Endocr J 49:85-90. 2002
    ..The patients with metastatic prostate cancer with low serum testosterone were in the high risk group of worse response to endocrine therapy. Additional therapy might be considered in those patients...
  31. ncbi request reprint A case of orbital metastasis from prostatic carcinoma as an initial symptom
    Shinzo Isshiki
    Department of Urology, Teikyo University Chiba Medical Center
    Hinyokika Kiyo 53:193-5. 2007
    ..The orbital tumor was surgically removed and endocrine therapy was performed subsequently. Metastatic carcinoma of the prostate should be considered in the elderly male with exophthalmos...
  32. ncbi request reprint Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma
    Osamu Nagakawa
    Department of Urology, Toyama Medical and Pharmaceutical University, Sugitani, Toyama, Japan
    Urology 60:527-30. 2002
    ..To clarify whether serum levels of pro-gastrin-releasing peptide (ProGRP) (31-98) could be a useful marker in patients with prostatic carcinoma. GRP is produced and secreted by prostatic neuroendocrine cells...
  33. ncbi request reprint Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer
    Shoichiro Ohta
    Department of Urology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, 930 0194, Japan
    Anticancer Res 22:2991-6. 2002
    ..Tissue factor (TF), the main initiator of blood coagulation, is involved in cancer metastasis and progression. We examined the role of TF on prostate cancer...
  34. ncbi request reprint Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer
    Shoichiro Ohta
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630, Sugitani, Toyama, Japan
    Anticancer Res 23:2945-50. 2003
    ..The present study was performed to evaluate the significance of expression of u-PA on the progression of prostate cancer...
  35. ncbi request reprint CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy
    Hiroyoshi Suzuki
    Department of Urology, Graduate School of Medicine, Chiba University Hospital, 1 8 1 Inohana, Chuo Ku, Chiba 260 8670, Japan
    Prostate 51:219-24. 2002
    ..Because the clinical significance of CAG repeat length during the course of prostate cancer in Japanese patients is unknown, the present study analyzed CAG repeat length in relation to several potential clinical factors...
  36. ncbi request reprint Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer
    Yoko Kawana
    Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan
    Prostate 53:60-4. 2002
    ....
  37. ncbi request reprint Primary adenocarcinoma of the appendix invading the urinary bladder
    Remon Nishio
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani 2630, 930 0194, Toyama, Japan
    Int Urol Nephrol 38:481-2. 2006
    ..The patient died of carcinoma 13 months later...
  38. ncbi request reprint Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer
    Yuzo Furuya
    Department of Urology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan
    Int Urol Nephrol 37:69-71. 2005
    ..Patients with hormone-resistant prostate cancer had a significantly higher level of IL-11 than those with untreated cancer. Serum IL-11 levels may be a potential tumor marker for prostate cancer progression...